Mar 19 |
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
|
Mar 14 |
Citi starts Catalyst at buy, cites rare disease drug portfolio
|
Mar 13 |
Catalyst announces US launch of Duchenne drug Agamree
|
Mar 13 |
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
|
Mar 7 |
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
|
Mar 5 |
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
|
Feb 29 |
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Top 3 Health Care Stocks You May Want To Dump In Q1
|
Feb 29 |
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
|
Feb 28 |
Catalyst Pharmaceuticals Non-GAAP EPS of $0.53 beats by $0.07, revenue of $110.57M beats by $4.65M
|